Home/Filings/4/0001104659-25-060652
4//SEC Filing

Fisher Andrew 4

Accession 0001104659-25-060652

CIK 0001657312other

Filed

Jun 17, 8:00 PM ET

Accepted

Jun 18, 4:31 PM ET

Size

10.3 KB

Accession

0001104659-25-060652

Insider Transaction Report

Form 4
Period: 2025-06-16
Fisher Andrew
General Counsel
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2025-06-16$2.01/sh+80,000$160,904439,999 total
  • Exercise/Conversion

    Share Options (Right to Buy)

    2025-06-1680,0002,240,000 total
    Exercise: $2.01Exp: 2034-03-31Ordinary Shares (80,000 underlying)
  • Sale

    Ordinary Shares

    2025-06-16$11.53/sh80,000$922,000359,999 total
Footnotes (6)
  • [F1]Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
  • [F2]The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan entered into on January 15, 2025.
  • [F3]The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $11.3994 to $11.7825 per Ordinary Share, inclusive (or $91.195 to $94.26 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  • [F4]Consists of (i) 300,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 37,500 ADSs), (ii) 59,992 Ordinary Shares underlying 7,499 ADSs, and (iii) 7 Ordinary Shares.
  • [F5]The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.
  • [F6]The option vested and became exercisable as to 25% on March 4, 2025. The remainder of the shares vested or will vest in 36 equal monthly installments thereafter.

Issuer

Verona Pharma plc

CIK 0001657312

Entity typeother

Related Parties

1
  • filerCIK 0002014301

Filing Metadata

Form type
4
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 4:31 PM ET
Size
10.3 KB